Bluejay Diagnostics, Inc. (BJDX) Current Ratio
- Current ratio · latest quarter: Value 4.64×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.64× | Current assets / current liabilities. $9.81M ÷ $2.12M ≈ 4.64× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 9.81M USD | Assets, Current |
| Current obligations | 2.12M USD | Liabilities, Current |
| Cash and equivalents | 9.60M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | Inventory, Net |
| Payables | 674.09K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.81M | $2.12M | $9.60M | (m) | (m) | (m) | $674.09K | (m) | 4.64× |
| 2026-03-31 | $3.97M | $1.41M | $3.68M | (m) | (m) | (m) | $220.29K | (m) | 2.81× |
| 2025-12-31 | $5.46M | $1.12M | $5.16M | (m) | (m) | (m) | $214.25K | (m) | 4.88× |
| 2025-09-30 | $3.35M | $1.15M | $3.08M | (m) | (m) | (m) | $161.16K | (m) | 2.92× |
| 2025-06-30 | $4.75M | $1.04M | $4.44M | (m) | (m) | (m) | $108.82K | (m) | 4.56× |
| 2025-03-31 | $3.57M | $1.32M | $3.12M | (m) | (m) | (m) | $519.52K | (m) | 2.71× |
| 2024-12-31 | $4.90M | $810.37K | $4.30M | (m) | (m) | (m) | $145.12K | (m) | 6.05× |
| 2024-09-30 | $6.57M | $1.05M | $5.76M | (m) | (m) | (m) | $316.65K | (m) | 6.26× |
| 2024-06-30 | $9.02M | $2.06M | $8.06M | (m) | (m) | (m) | $490.06K | (m) | 4.38× |
| 2024-03-31 | $3.45M | $1.53M | $2.66M | (m) | (m) | (m) | $271.82K | (m) | 2.26× |
| 2023-12-31 | $3.22M | $1.77M | $2.21M | (m) | (m) | (m) | $491.47K | (m) | 1.82× |
| 2023-09-30 | $6.53M | $2.80M | $5.08M | (m) | (m) | (m) | $755.95K | (m) | 2.33× |
| 2023-06-30 | $6.58M | $1.83M | $5.10M | (m) | (m) | (m) | $271.49K | (m) | 3.59× |
| 2023-03-31 | $8.90M | $1.42M | $6.78M | (m) | (m) | (m) | $388.05K | (m) | 6.27× |
| 2022-12-31 | $11.79M | $1.64M | $10.11M | (m) | (m) | (m) | $635.82K | (m) | 7.19× |
| 2022-09-30 | $13.94M | $1.52M | $13.29M | (m) | (m) | (m) | $443.04K | (m) | 9.15× |
| 2022-06-30 | $17.05M | $979.59K | $15.34M | (m) | (m) | $671.25K | $196.11K | (m) | 17.41× |
| 2022-03-31 | $19.32M | $1.31M | $17.12M | (m) | (m) | $893.17K | $716.84K | (m) | 14.75× |
| 2021-12-31 | $20.66M | $637.16K | $19.05M | (m) | (m) | (m) | $295.78K | (m) | 32.43× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |